Home >Current Issue
Volume: 9, Issue: 8, August, 2019
Validation of an HPLC-MS method for the determinatin of vardenafil in rat urineAuthor Affiliations
A simple and accurate technique of high-performance liquid chromatography with mass spectrometry was developed for the quantitative determination of vardenafil and its metabolites in urine. Extraction of vardenafil and internal standard (sildenafil) was performed from 5 ml of urine with 1,2-dichloroethane at pH = 7.5, followed by purification of samples on Oasis HLB cartridges. Chromatographic separation was carried out on a Zorbax SB-C18 reversed-phase column (50 mm × 2.1 mm) in linear gradient mode, at a rate of 0.4 ml/minute. Mobile phase composition: 0.1% aqueous formic acid solution and 0.1% formic acid solution in acetonitrile. Detection of vardenafil and sildenafil in samples was performed using a single quadrupole mass spectrometer with electrospray ionization. Mass spectral analysis was performed in the m/z range: 50–500 with the fragmentation of 50 m/z under positive ionization. The linear dependence for vardenafil was in the range of 7–500 ng/ml; limit of detection and limit of quantification were 5 and 7 ng/ml, respectively. The developed method was tested on specimens of rat urine taking vardenafil at a dose of 0.28 mg/kg. 11.27–13.60 ng of vardenafil were detected in 1 ml of daily urine of the animals. This method is recommended for use in toxicological practice.
Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abu El-Enin MA, Al-Ghaffar HMS, El-Sherbiny DT, El- Wasseef DR, El-Ashry SM. Validated spectrofluorimetric method for determination of two phosphodiesterase inhibitors tadalafil and vardenafil in pharmaceutical preparations and spiked human plasma. Luminescence, 2016; 31:173-8. https://doi.org/10.1002/bio.2941
Al-Tahami K. Determination of sildenafil, vardenafil and tadalafil in dietary supplements sold in the Yemeni market. Int J Sci Res, 2014; 3(4):403-5. https://doi.org/10.15373/22778179/APR2014/143
Bayer Inc. LEVITRA® (vardenafil tablets 5 mg, 10 mg, 20 mg of vardenafil, as vardenafil hydrochloride)-Product Monograph. Mississauga, Ontario, 2015. Available via https://omr.bayer.ca/omr/online/ levitra-pm-en.pdf (Accessed 9 March 2019).
Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type-5 inhibitors. Expert Opin Pharmacother, 2013; 14(10):1333-44. https://doi.org/10.1517/14656566.2013.799665
Carlucci G, Palumbo P, Iuliani P, Palumbo G. Development of a method for the determination of vardenafil in human plasma by high performance liquid chromatography with UV detection. Biomed Chromatogr, 2009; 23(7):759-63. https://doi.org/10.1002/bmc.1181
Cheng CL, Kang GJ, Chou CH. Development and validation of a high-performance liquid chromatographic method using fluorescence detection for the determination of vardenafil in small volumes of rat plasma and bile. J Chromatogr A, 2007; 1154.1.2:222-9. https://doi.org/10.1016/j.chroma.2007.03.077
Chiang J, Yafi FA, Dorsey PJ, Hellstrom WJ. The dangers of sexual enhancement supplements and counterfeit drugs to "treat" erectile dysfunction. Transl Androl Urol, 2017; 6(1):12-9. https://doi.org/10.21037/tau.2016.10.04
DeBusk R, Drory Y, Goldstein I, Jackson G, Kaul S, Kimmel SE, Kostis JB, Kloner RA, Lakin M, Meston CM, Mittleman M, Muller JE, Padma-Nathan H, Rosen RC, Stein RA, Zusman R. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol, 2000; 86(2):175-81. https://doi.org/10.1016/S0002-9149(00)00896-1
European Medicines Agency. Levitra (International Nonproprietary Name: vardenafil). CHMP assessment report, London, 2010. Available via https://www.ema.europa.eu/en/documents/variation-report/levitra-h-c-475-x-28-epar-assessment-report-extension_en.pdf (Accessed 10 March 2019).
European Medicines Agency (EMEA/CHMP/ EWP/192217/2009). Guideline on bioanalytical method validation, London, 2011.
Eve D. Drug profile: Levitra. Medicine discovery, 2009. Available via http://www.discoverymedicine.com/David-Eve/2009/05/23/ drug-profile-levitrа (Accessed 15 March 2019).
Food, Drug Administration Centre for Drug Evaluation and Research (FDA). Guidance for industry-bioanalytical method validation, center for drug evaluation and research. US Department for Health and Human Services, 2013, Silver Spring, MD, 2001.
Gilard V, Balayssac S, Tinaugus A, Martins N, Martino R, Malet-Martino M. Detection, identification and quantification by 1H NMR of adulterants in 150 herbal dietary supplements marketed for improving sexual performance. J Pharm Biomed Anal, 2015; 102:476-93. https://doi.org/10.1016/j.jpba.2014.10.011
Hasegawa K, Suzuki O, Gonmori K, Yamagishi I, Nozawa H, Watanabe K. Simultaneous analysis of sildenafil, vardenafil, tadalafil, and their desalkyl metabolites in human whole blood and urine by isotope dilution LC-MS-MS. Forensic Toxicol, 2012; 30:25-32. https://doi.org/10.1007/s11419-011-0125-2
Jackson G, Arver S, Banks I,Stecher V.J. Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks. Int J Clin Pract, 2011; 64.4:497-504. https://doi.org/10.1111/j.1742-1241.2009.02328.x
Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, Jiang X, Galiè N. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med, 2011; 183(12):1723-9. https://doi.org/10.1164/rccm.201101-0093OC
Johnson RD, Lewis RJ, Angier MK. The postmortem distribution of vardenafil (Levitra) in an aviation accident victim with an unusually high blood concentration. J Anal Toxicol, 2007; 31(6):328-33. https://doi.org/10.1093/jat/31.6.328
Karasu-Minareci E, Ozbudak I.H, Ozbilim G, Sadan G. Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension. Sci World J, 2012; 2012:718279; doi:10.1100/2012/718279 https://doi.org/10.1100/2012/718279
Katlowitz NM, De Rosalio A. Phosphodiesterase type 5 inhibitors and nitrates: is concomitant use safe? Are there alternatives? Curr Sexual Health Rep, 2007; 4(2):59-63. https://doi.org/10.1007/s11930-007-0003-4
Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol, 2004; 27(1):20-5. https://doi.org/10.1002/clc.4960271306
Kloner АR, Henderson L. Sexual function in patients with chronic angina pectoris. Am J Cardiol, 2013; 111(1):1671-6. https://doi.org/10.1016/j.amjcard.2013.02.009
Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett A.L, Carson G, Cheitlin M, Debusk M, Fonseca V, Ganz P, Goldstein I, Guay A, Hatzichristou D, Hollander J. E, Hutter A, Katz S, Kloner R.A, Mittleman M, Montorsi F, Montorsi P, Nehra A, Sadovsky R, Shabsigh R. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol, 2005; 96(2):313-21. https://doi.org/10.1016/j.amjcard.2005.03.065
Lakea ST, Altmanb PM, Vaismanc J, Addisona RS. Validated LC-MS/MS assay for the quantitativ determination of vardenafi l in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr, 2010; 24:846-51; doi:10.1002/bmc.1375 https://doi.org/10.1002/bmc.1375
Papoutsis I, Nikolaou P, Athanaselis S, Pistos C, Maravelias C, Spiliopoulou C. A fully validated method for the determination of vardenafil in blood using gas chromatography/mass spectrometry. J Mass Spectrom, 2011;46(1):71-6. https://doi.org/10.1002/jms.1868
Proença P, Mustra C, Marcos M, Franco J.M, Corte-Real F, Vieira D.N. Validated UPLC-MS/MS assay for the determination of synthetic phosphodiesterase type-5 inhibitors in postmortem blood samples. J Forensic Leg Med, 2013; 20(6):655-8. https://doi.org/10.1016/j.jflm.2013.03.002
Reeuwijk NM, Venhuis BJ, de Kaste D, Hoogenboom LA, Rietjens IM, Martena MJ. Sildenafil and analogous phosphodiesterase type 5 (PDE-5) inhibitors in herbal food supplements sampled on the Dutch market. Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2013; 30(12):2027-34. https://doi.org/10.1080/19440049.2013.848294
Rust KY, Wilkens H, Kaiser R, Bregel D, Wilske J, Kraemer T. Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS-application to forensic and therapeutic drug monitoring cases. Ther Drug Monit, 2012; 34(6):729-35. https://doi.org/10.1097/FTD.0b013e31827318b8
Schnetzler G, Banks I, Kirby M, Zou KH, Symonds T. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors. J Sex Med, 2010; 7(3):1237-46. https://doi.org/10.1111/j.1743-6109.2009.01674.x
Singh S, Prasad B, Savaliya AA, Shah RP, Gohil VM, Kaur A. Strategies for characterizing sildenafil, vardenafil, tadalafil and their analogues in herbal dietary supplements, and detecting counterfeit products containing these drugs. TrAC Trends Analyt Chem, 2009; 28(1):13-28. https://doi.org/10.1016/j.trac.2008.09.004
Strano-Rossi S, Anzillotti L, Torre X, Botre F. A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine. Rapid Commun Mass Spectrom, 2010; 24:1697-706. https://doi.org/10.1002/rcm.4568
Walker MJ, Naughton DP, Deshmukh N, Burns, DT. A review of methods for the simultaneous detection of illegal ingredients in food supplements. J Assoc Public Anal, 2016; 44:51-6. Available via http://www. apajournal.org.uk/2016_0051-0066.pdf (Accessed 20 February 2019).
Xiao C, Tang M, Li J, Yin CR, Xiang G, Xu L. Determination of sildenafil, vardenafil and aildenafil in human plasma by dispersive liquid- liquid microextraction-back extraction based on ionic liquid and high performance liquid chromatography-ultraviolet detection. J Chromatogr B Anal Technol Biomed Life Sci, 2013; 931:111-6. https://doi.org/10.1016/j.jchromb.2013.05.013